Axogen director sells 3,500 shares at ~$49.70

Axogen, Inc. (AXGN) director Joseph A. Tyndall reported selling 3,500 shares of common stock on September 2, 2026 in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Axogen, Inc. (AXGN) director Joseph A. Tyndall reported selling 3,500 shares of common stock on September 2, 2026 in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. The weighted average sale price was about $49.70 per share, and he now directly holds 10,650 shares of Axogen common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,500 shares

Net Sell 1 txn

Insider TYNDALL JOSEPH A.

Role Director

Sold 3,500 shs ($174K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,500	$49.697	$174K

Holdings After Transaction: Common Stock — 10,650 shares (Direct)

Footnotes (2)

1. F1. The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.
2. F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,500 shares Weighted average sale price: $49.697 per share Sale price range: $48.01–$51.46 per share +3 more

6 metrics

Shares sold 3,500 shares Common stock sold by director on September 2, 2026

Weighted average sale price $49.697 per share Average price for the 3,500 shares sold

Sale price range $48.01–$51.46 per share Range of prices across multiple sale transactions

Shares held after transaction 10,650 shares Director’s direct Axogen common stock holdings following the sale

Net shares sold 3,500 shares Net disposition across all reported transactions in this Form 4

Rule 10b5-1 plan adoption date June 3, 2026 Date the trading plan governing this sale was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axogen (AXGN) report in this Form 4?

Axogen reported that director Joseph A. Tyndall sold 3,500 shares of Axogen common stock on September 2, 2026 in an open-market or private sale transaction.

At what price were the Axogen (AXGN) shares sold by the director?

The sale was reported at a weighted average price of $49.697 per share. A footnote states the shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share.

How many Axogen (AXGN) shares does the insider hold after this sale?

After the reported sale, director Joseph A. Tyndall directly holds 10,650 shares of Axogen common stock, according to the Form 4 disclosure.

Was the Axogen (AXGN) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 3, 2026, and the Rule 10b5-1 checkbox is affirmed.

How many Axogen (AXGN) shares in total were sold in this Form 4 transaction?

The Form 4 reports a single transaction in which 3,500 shares of Axogen common stock were sold, with no purchases or derivative exercises reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:08 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TYNDALL JOSEPH A.

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		3,500	D	$49.697(2)	10,650	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.

2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Marc Began as attorney-in-fact for Joseph A. Tyndall	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)